Business Context and Reporting Period
Cytosorbents Corp (CTS) filed a Form 8-K on June 29, 2026, reporting a notice from the Nasdaq Stock Market LLC regarding non-compliance with continued listing standards. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, or debt. The only financial metric disclosed is the Market Value of Listed Securities (MVLS), which was reported as being below the required minimum of $35 million. The filing also notes a potential alternative compliance path involving stockholders' equity of at least $2.5 million.
Material Changes
The material change is the receipt of a formal notice from Nasdaq indicating the company failed to meet Listing Rule 5550(b)(2) due to insufficient MVLS. This represents a deviation from the standard listing requirements necessary to maintain the company's status on the Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
- Compliance Period: Nasdaq has granted the company 180 calendar days, until December 28, 2026, to regain compliance.
- Remediation Strategy: The company must maintain an MVLS of at least $35 million for 10 consecutive business days during the grace period. Alternatively, the company may consider increasing stockholders' equity to at least $2.5 million.
- Risks: There is no assurance the company will successfully maintain its listing. Failure to comply by the deadline will result in a delisting notification, at which point the company may appeal.
- Current Status: The notice does not result in immediate delisting.
Investor Verification Checklist
- Verify the current market capitalization and whether it has approached the $35 million threshold.
- Monitor the company's stock price volatility over the next 10 consecutive business days to assess compliance progress.
- Review upcoming filings for any announcements regarding equity raises or other capital actions intended to boost stockholders' equity to $2.5 million.
- Check for any subsequent communications from Nasdaq regarding extensions or delisting determinations.